Ministry for Primary Industries
Manatū Ahu Matua

Ref: CTO 2014 76 [G]

Health Supplements/Chinese and Oriental Medicines: Importation into Transitional Facility for further processing

CTO direction to biosecurity inspectors for the direction of Health Supplements/Chinese and Oriental Medicines into a Transitional Facility for further processing

Pursuant to section 27(1)(d)(iii) of the Biosecurity Act 1993 I, Vicki Melville, Manager Animal Imports, Ministry for Primary Industries (under delegated authority), give the following directions for Health Supplements/Chinese and Oriental Medicines to be given direction in accordance with the following measures, different from those in the applicable import health standard for the Importation into New Zealand of Specified Animal Products and Biologicals [INEPROIC.ALL]:

Under clause 6.1.1, Health supplements/Chinese and Oriental medicines containing animal products species that are commercially manufactured and compounded into pills, tablets, capsules, liquids, syrups, oils or medicated plasters may be imported.

Raw material originating from various animal and plant species are often imported for processing into health supplements/Chinese and Oriental medicines in New Zealand. After assessing risk analysis advice, it has been deemed that the biosecurity risk associated with these raw material would be effectively mitigated if they are brought into a Transitional Facility approved and operating to TF Gen Annex F standard and processed into pills, tablets, capsules, liquids, syrups, oils or medicated plasters.

At the Transitional Facility, the product must be processes to meet the eligibility criteria in clause 6.1 of INEPROIC.ALL

6.1 Health supplements/Chinese and Oriental medicines containing animal products *from* any country may be given clearance provided all the following requirements are met:

i. The product shall be commercially manufactured and compounded into pills, tablets, capsules, liquids, syrups, oils or medicated plasters.
ii. The product shall be shelf-stable (i.e. not require refrigeration)
iii. The packaging or appearance of the packaging shall not indicate that the product is intended for animal use
iv. If the product is a liquid, it shall be contained within sealed packaging.
(NB: medicines containing bee products are not eligible for importation under clause 6.1.)

This CTO direction is not applicable for raw material originating from bees.

The reason for directing clearance is that the biosecurity risks associated with this CTO direction have been assessed and are managed effectively.

This direction takes effect from the date of signing and continues in effect until amended or revoked.

Standards
Animal and Animal Products Directorate
Pastoral House, 25 The Terrace, PO Box 2526
Wellington 6140, New Zealand
Telephone: 0800 00 83 33, Facsimile: +64-4-894 0300
www.mpi.govt.nz